Original Research ARTICLE
Sophocarpine suppresses NF-κB-mediated inflammation both in vitro and in vivo and inhibits diabetic cardiomyopathy
- 1Second Affiliated Hospital of Nanchang University, China
- 2Second Affiliated Hospital of Nanchang University, China
Diabetic cardiomyopathy (DCM) is a leading cause of mortality in patients with diabetes. Diabetic cardiomyopathy (DCM) is a leading cause of mortality in patients with diabetes. We used both in vitro and in vivo experiments to investigate the hypothesis that sophocarpine (SPC), a natural quinolizidine alkaloid derived from a Chinese herb, could protect against DCM. We used hyperglycemic myocardial cells and a streptozotocin (STZ)-induced type 1 diabetes mellitus mouse model. SPC protected myocardial cells from hyperglycemia-induced injury by improving mitochondrial function, suppressing inflammation, and inhibiting cardiac apoptosis. The SPC treatment significantly inhibited the activation of nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) signaling in high-glucose-stimulated inflammatory responses. Moreover, SPC significantly slowed the development and progression of DCM in STZ-induced diabetic mice. These results show that SPC suppresses NF-κB-mediated inflammation both in vitro and in vivo and may be used to treat DCM.
Keywords: Sophocarpine, NF-κB, Inflammation, Diabetis, Cardiomyopathy - diagnostics
Received: 24 Jun 2019;
Accepted: 23 Sep 2019.
Copyright: © 2019 Zou, Wang, Liu, Wang, Hu, Xiong, Wu, Shen and Yang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Dr. Yunfeng Shen, Second Affiliated Hospital of Nanchang University, Nanchang, China, email@example.com